Stockmark.IT - Global News Affecting Stock Markets and Investments

Two syringes with orange caps rest on a wooden surface, next to a medication vial. The vial has text and labels, partially visible, indicating medical use. The background is out of focus.

Illicit Drug Dealers Expand Product Lines to Include Premium Weight Loss Medications

In an unprecedented shift within the underground pharmaceutical market, drug dealers across the UK are diversifying their offerings to include sought-after weight-loss medications alongside traditional illicit substances. The weight-loss injection

A healthcare professional wearing a surgical gown, mask, and cap concentrates on a procedure in a well-lit operating room. Medical equipment and monitors are visible in the background, suggesting a hospital setting.

NHS1 year ago

Private Healthcare Giant Spire Sees Record NHS Partnerships and Profit Growth

Spire Healthcare, the UK’s largest private healthcare provider, is witnessing unprecedented growth amid mounting NHS pressures. The FTSE 250-listed organisation has strategically positioned itself as a crucial partner in addressing

AstraZeneca building; strategic technology partnership. from Stockmark.it

Healthcare1 year ago

AstraZeneca Board Welcomes Arm Holdings CEO in Strategic Technology Push

In a significant move strengthening its technological capabilities, AstraZeneca has appointed Arm Holdings Chief Executive Rene Haas to its board as a non-executive director, effective from next month. The appointment

Syringe and vaccine vial on blue background. from Stockmark.it

Financial1 year ago

GSK Maintains Annual Forecast Despite Vaccine Division Setback as New Drug Portfolio Shows Promise

British pharmaceutical giant GSK has held firm on its annual group forecasts despite experiencing a decline in vaccine sales, with strong performance in specialist medicines helping to offset the downturn.

A glowing medicine vial is centred in a futuristic laboratory, with scientists at computers. Text reads Syntara’s £10m raise fuelling drug trials to mid-2025, amid breakthroughs comparable to rare earth discoveries. A video play bar is visible at the bottom. @ stockmark.it

Drug Research2 years ago

Syntara’s $10M Raise: Fueling Drug Development

Syntara's $10M capital raise is propelling its drug development strategy into a new era. In this exclusive interview, CEO Gary Phillips unveils the transformative steps taken by Syntara Ltd, from its rebranding efforts to the strategic deployment of funds.